

Attachment 5a. Test Kit Application and Questions for US Laboratories (Word)

CDC estimates the average public reporting burden for this collection of information as 6 minutes per response, including the time for reviewing instructions, searching existing data/information sources, gathering, and maintaining the data/information needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB Control Number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Information Collection Review Office, 1600 Clifton Road NE, MS D-74, Atlanta, Georgia 30333; ATTN: PRA (0920-1313).

OMB No. 0920-1313
Exp. Date 03/31/2026

Applicant Information

First Name

Last Name

Institution

Lab Name (optional)

Street Address Line 1

Street Address Line 2

City

State (dropdown) * This field is required

Zip/Postal Code

Email

Verify Email

Telephone

Does your laboratory have a current DEA registration to handle scheduled substances?
 [YES/NO] * This field is required

Testing Information

1. Which test kit(s) are you requesting? (provide quantity)

Fentanyl Analog Screening (FAS)	Quantity <input type="text"/>
FAS Version 1	Quantity <input type="text"/>
FAS Version 2 and 3	Quantity <input type="text"/>
FAS Version 4	Quantity <input type="text"/>
Emergent Drug Panel (EDP)	Quantity <input type="text"/>
Emergent Drug Panel - Version 1 (EDP-V1)	Quantity <input type="text"/>
Emergent Drug Panel - Internal Standard (EDP-IS)	Quantity <input type="text"/>
2. Which test kit(s) have you previously received? (provide quantity)

Fentanyl Analog Screening (FAS)	Quantity <input type="text"/>
FAS Version 1	Quantity <input type="text"/>

FAS Version 2 and 3	Quantity [__]
FAS Version 4	Quantity [__]
Emergent Drug Panel (EDP) [__]	Quantity
Emergent Drug Panel - Version 1 (EDP-V1) [__]	Quantity
Emergent Drug Panel - Internal Standard (EDP-IS) [__]	Quantity

3. Which of the following best describes your laboratory? (Select only one)

- Academic Research Laboratory
- Environmental Laboratory
- Government Crime Laboratory
- Government Toxicology Laboratory
- Private or Public Clinical Laboratory
- Other (please specify) _____

4. Which of the following tests or services are performed by your laboratory? (Select all that apply)

- Seized drug sample testing
- Post-mortem toxicology sample testing
- Workplace drug screening
- Newborn drug screening
- Drug pharmacology and pharmacokinetics research
- Clinical testing for disease diagnosis and treatment or surveillance
- Other (please specify) _____

5. Which of the following drug categories does your laboratory test for? (Select all that apply)

- Opioids
- Synthetic Cannabinoids
- Stimulants and Hallucinogens
- Benzodiazepines

6. On average, how many opioid, synthetic cannabinoid, stimulant, hallucinogen, or benzodiazepine-related samples does your laboratory analyze on a weekly basis? (Select only one)

- < 100

- 100 - 500
- 501 - 1000
- > 1000

7. Which of the following analytical techniques do you perform in your laboratory? (Select all that apply)

- Immunoassay
- Infrared Spectroscopy
- Mass Spectrometry
- Nuclear Magnetic Resonance Spectroscopy
- Raman Spectroscopy
- X-ray Diffraction
- Chromatographic Separation
- UV/Vis
- Other (please specify) _____

8. Which sample matrices does your laboratory analyze? (Select all that apply)

- Blood
- Urine
- Drug Powders
- Waste Water
- Other (please specify) _____

Submit